Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 8 | 2022 | 27 | 3.960 |
Why?
|
| Kidney Transplantation | 10 | 2024 | 114 | 3.710 |
Why?
|
| Organ Transplantation | 4 | 2022 | 32 | 1.600 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 27 | 1.530 |
Why?
|
| Graft Rejection | 7 | 2024 | 61 | 1.480 |
Why?
|
| Cytomegalovirus | 5 | 2022 | 15 | 1.480 |
Why?
|
| Transplant Recipients | 7 | 2023 | 21 | 1.320 |
Why?
|
| HIV Infections | 6 | 2024 | 424 | 1.120 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3040 | 1.070 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 7 | 1.000 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 113 | 0.980 |
Why?
|
| Inpatients | 4 | 2023 | 116 | 0.950 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 12 | 0.950 |
Why?
|
| Patient Readmission | 3 | 2015 | 117 | 0.940 |
Why?
|
| Humans | 34 | 2025 | 23331 | 0.800 |
Why?
|
| Daptomycin | 1 | 2022 | 10 | 0.770 |
Why?
|
| Antiviral Agents | 3 | 2022 | 66 | 0.770 |
Why?
|
| Kidney Failure, Chronic | 3 | 2024 | 123 | 0.770 |
Why?
|
| Antimicrobial Stewardship | 1 | 2022 | 18 | 0.770 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 155 | 0.750 |
Why?
|
| Immunosuppressive Agents | 4 | 2016 | 113 | 0.720 |
Why?
|
| Adult | 15 | 2022 | 7070 | 0.720 |
Why?
|
| Cross Infection | 1 | 2023 | 297 | 0.680 |
Why?
|
| Hypoglycemia | 1 | 2020 | 12 | 0.670 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 35 | 0.660 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 30 | 0.660 |
Why?
|
| Antifungal Agents | 2 | 2018 | 38 | 0.660 |
Why?
|
| Electronic Health Records | 1 | 2020 | 66 | 0.640 |
Why?
|
| United States | 8 | 2022 | 1829 | 0.610 |
Why?
|
| Lung Transplantation | 2 | 2016 | 6 | 0.600 |
Why?
|
| Liver Transplantation | 2 | 2021 | 91 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 363 | 0.590 |
Why?
|
| Risk Factors | 8 | 2022 | 1998 | 0.570 |
Why?
|
| Middle Aged | 14 | 2024 | 8055 | 0.560 |
Why?
|
| Cryptococcosis | 1 | 2018 | 6 | 0.560 |
Why?
|
| Population Health | 1 | 2018 | 4 | 0.560 |
Why?
|
| Consensus | 1 | 2018 | 85 | 0.550 |
Why?
|
| Male | 18 | 2025 | 12629 | 0.530 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.530 |
Why?
|
| Yeasts | 1 | 2017 | 3 | 0.530 |
Why?
|
| Dermatomycoses | 1 | 2017 | 4 | 0.530 |
Why?
|
| Fungemia | 1 | 2017 | 7 | 0.530 |
Why?
|
| Exanthema | 1 | 2017 | 11 | 0.530 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.520 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 11 | 0.510 |
Why?
|
| Roseolovirus Infections | 1 | 2016 | 3 | 0.510 |
Why?
|
| Bacteremia | 1 | 2016 | 98 | 0.480 |
Why?
|
| Liver Failure | 1 | 2015 | 10 | 0.460 |
Why?
|
| Aged | 9 | 2022 | 7552 | 0.450 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 13 | 0.450 |
Why?
|
| Heart Transplantation | 1 | 2014 | 29 | 0.440 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 12 | 0.440 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 83 | 0.420 |
Why?
|
| Tissue Donors | 5 | 2024 | 63 | 0.390 |
Why?
|
| Female | 14 | 2025 | 13124 | 0.380 |
Why?
|
| Young Adult | 6 | 2021 | 1674 | 0.380 |
Why?
|
| Time Factors | 5 | 2016 | 1289 | 0.380 |
Why?
|
| Tissue and Organ Procurement | 2 | 2024 | 30 | 0.380 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 42 | 0.370 |
Why?
|
| Postoperative Complications | 2 | 2024 | 836 | 0.360 |
Why?
|
| Graft Survival | 4 | 2024 | 84 | 0.350 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.350 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 274 | 0.350 |
Why?
|
| Incidence | 3 | 2021 | 636 | 0.350 |
Why?
|
| Hospital Mortality | 3 | 2015 | 133 | 0.320 |
Why?
|
| Ganciclovir | 2 | 2022 | 8 | 0.320 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 289 | 0.320 |
Why?
|
| Databases, Factual | 2 | 2021 | 314 | 0.260 |
Why?
|
| Directly Observed Therapy | 1 | 2006 | 2 | 0.260 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 59 | 0.250 |
Why?
|
| HIV Seropositivity | 1 | 2006 | 49 | 0.250 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 813 | 0.240 |
Why?
|
| Comorbidity | 3 | 2021 | 431 | 0.240 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1441 | 0.240 |
Why?
|
| Trees | 1 | 2025 | 19 | 0.230 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 125 | 0.220 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 104 | 0.220 |
Why?
|
| Adolescent | 3 | 2025 | 1916 | 0.220 |
Why?
|
| Cohort Studies | 3 | 2022 | 1429 | 0.210 |
Why?
|
| Kidney | 2 | 2023 | 142 | 0.210 |
Why?
|
| Asthma | 1 | 2025 | 150 | 0.200 |
Why?
|
| Hospitalization | 2 | 2021 | 290 | 0.200 |
Why?
|
| Linezolid | 1 | 2022 | 4 | 0.200 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 83 | 0.190 |
Why?
|
| Benchmarking | 1 | 2022 | 28 | 0.190 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 53 | 0.190 |
Why?
|
| Carbapenems | 1 | 2022 | 45 | 0.190 |
Why?
|
| Vancomycin | 1 | 2022 | 52 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2022 | 11 | 0.190 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 68 | 0.190 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 17 | 0.180 |
Why?
|
| Medicare | 1 | 2022 | 108 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 3783 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2021 | 43 | 0.170 |
Why?
|
| Pancreas | 1 | 2021 | 30 | 0.170 |
Why?
|
| Rectal Prolapse | 1 | 2021 | 1 | 0.170 |
Why?
|
| Forecasting | 1 | 2021 | 82 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 53 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 24 | 0.170 |
Why?
|
| HIV-1 | 1 | 2022 | 202 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 66 | 0.160 |
Why?
|
| Insulin | 1 | 2020 | 78 | 0.160 |
Why?
|
| Biomarkers | 1 | 2022 | 487 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2025 | 175 | 0.150 |
Why?
|
| Models, Biological | 1 | 2021 | 306 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2021 | 183 | 0.150 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 2 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 31 | 0.130 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.130 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cryptococcus | 1 | 2017 | 3 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 6 | 0.130 |
Why?
|
| Amphotericin B | 1 | 2017 | 5 | 0.130 |
Why?
|
| Trichosporon | 1 | 2017 | 2 | 0.130 |
Why?
|
| Cytarabine | 1 | 2017 | 11 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2017 | 9 | 0.130 |
Why?
|
| Echinocandins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Vidarabine | 1 | 2017 | 8 | 0.130 |
Why?
|
| Voriconazole | 1 | 2017 | 10 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 8 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2017 | 32 | 0.130 |
Why?
|
| Fever | 1 | 2017 | 32 | 0.130 |
Why?
|
| Paecilomyces | 1 | 2016 | 2 | 0.130 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 2 | 0.130 |
Why?
|
| Herpesvirus 7, Human | 1 | 2016 | 2 | 0.130 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 10 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 192 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 36 | 0.120 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 7 | 0.120 |
Why?
|
| Medicare Part D | 1 | 2016 | 5 | 0.120 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 3 | 0.120 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 13 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 34 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 104 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 240 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2988 | 0.110 |
Why?
|
| Florida | 1 | 2014 | 17 | 0.110 |
Why?
|
| California | 1 | 2014 | 35 | 0.110 |
Why?
|
| Income | 1 | 2014 | 66 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 740 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2021 | 380 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 641 | 0.090 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 10 | 0.090 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 8 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 9 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 109 | 0.080 |
Why?
|
| Genotype | 1 | 2011 | 246 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 203 | 0.080 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.080 |
Why?
|
| Shellfish | 1 | 2009 | 2 | 0.080 |
Why?
|
| Urban Health | 1 | 2006 | 20 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2006 | 94 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 145 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 270 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2023 | 18 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 17 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2025 | 578 | 0.050 |
Why?
|
| Disease Progression | 1 | 2025 | 525 | 0.050 |
Why?
|
| Health Facilities | 1 | 2023 | 26 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.050 |
Why?
|
| Proviruses | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 16 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 14 | 0.050 |
Why?
|
| Chicago | 1 | 2025 | 819 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2022 | 3 | 0.050 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2022 | 2 | 0.050 |
Why?
|
| Child | 1 | 2025 | 1171 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 157 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2021 | 130 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2021 | 22 | 0.040 |
Why?
|
| Perineum | 1 | 2021 | 5 | 0.040 |
Why?
|
| Infection Control | 1 | 2022 | 169 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 102 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 146 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 1523 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 272 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 6 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 27 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 10 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 33 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 323 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 47 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 162 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 593 | 0.030 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Food Contamination | 1 | 2009 | 2 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 7 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 8 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 25 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 322 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 3287 | 0.010 |
Why?
|